Live Quote · OTCOTLCHealthcare · Biotechnology

Oncotelic Therapeutics, Inc.

$0.02▼ 16.67%($-0.00)

MKT CAP $8.87MNEXT EARNINGS Nov 18, 2026

50%

Bullish

50%

Bullish

TickerSpark Score

53/100

▌ Mixed

60

Valuation

80

Profitability

60

Growth

36

Health

30

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OTLC research report →

Price Chart

-76.64% · this period

52-Week Range5% of range

Low

$0.01

Current

$0.02

High

$0.11

Float & Shares

Free Float: 50.2%
Shares Outstanding: 443.62M
Float Shares: 222.81M

Insider ActivityLast quarter

1 Buys0 Sells

Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jul 10, 26	Fein Seymour Howard	officer: CRO/CMO	other	250	$0
Jul 10, 26	KING STEVEN W	director	other	250	$0
Jul 10, 26	MAIDA ANTHONY E III	director, officer: DIRECTOR AND CMO - TRANS. MED.	other	1,500	$0
Jul 10, 26	Saund Saran	officer: CBO	other	1,500	$0
Jul 10, 26	Shah Amit B.	officer: CFO	other	1,500	$0
Jul 10, 26	Trieu Vuong	director, 10 percent owner, officer: CHAIRMAN AND CEO	other	2,000	$0
Jul 1, 26	Trieu Vuong	director, 10 percent owner, officer: CHAIRMAN AND CEO	buy	240,000	$10.34K
Jun 24, 26	Trieu Vuong	director, 10 percent owner, officer: CHAIRMAN AND CEO	buy	115,000	$5.17K
Jun 23, 26	Trieu Vuong	director, 10 percent owner, officer: CHAIRMAN AND CEO	buy	75,000	$3.38K
Jun 22, 26	Trieu Vuong	director, 10 percent owner, officer: CHAIRMAN AND CEO	buy	65,000	$2.92K

A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.

Oncotelic Therapeutics, Inc.

Price Chart

About the company

Get TickerSpark's AI analysis on OTLC

Similar companies

Recent insider transactions

Our OTLC coverage

No research on OTLC yet